Results from pivotal study published in Diagnostics journalConfirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher diseaseCould predict clinical course of patients and improve personalized care CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2023 (GLOBE NEWSWIRE) CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data confirming the
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Q2 2023 Earnings Call Transcript August 15, 2023 Freeline Therapeutics Holdings plc misses on earnings expectations. Reported EPS is $-4.16 EPS, expectations were $3.62. Operator: Good morning, everyone, and welcome to the Freeline Second Quarter 2023 Financial and Business Update Conference Call. All participants will be in a listen-only mode. […]